Jonathan R. Brody

11.7k total citations · 1 hit paper
184 papers, 7.2k citations indexed

About

Jonathan R. Brody is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jonathan R. Brody has authored 184 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 101 papers in Molecular Biology and 59 papers in Cancer Research. Recurrent topics in Jonathan R. Brody's work include Pancreatic and Hepatic Oncology Research (79 papers), Cancer Genomics and Diagnostics (40 papers) and RNA modifications and cancer (26 papers). Jonathan R. Brody is often cited by papers focused on Pancreatic and Hepatic Oncology Research (79 papers), Cancer Genomics and Diagnostics (40 papers) and RNA modifications and cancer (26 papers). Jonathan R. Brody collaborates with scholars based in United States, Israel and Switzerland. Jonathan R. Brody's co-authors include Scott E. Kern, Charles J. Yeo, Agnieszka K. Witkiewicz, Jordan M. Winter, Michael J. Pishvaian, Joseph A. Cozzitorto, Michael P. Lisanti, Eike Gallmeier, Christina L. Costantino and Abhijit Dasgupta and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jonathan R. Brody

178 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

2020 327 citations Michael J. Pishvaian, Edik M. Blais et al. profile →

Peers

Jonathan R. Brody

ONCOL

PRM

IMMUN

Tamer T. Önder Türkiye

Asha S. Multani United States

Marcella Mottolese Italy

Giuseppe Viglietto Italy

Vladimir Lazar France

Piotr Rychahou United States

Eric J. Bernhard United States

Robert Zeillinger Austria

Angelika Eggert Germany

Gema Moreno‐Bueno Spain

Tamer T. Önder Türkiye

Jonathan R. Brody

5.9k ×1.4

3.3k ×1.0

ONCOL

2.5k ×1.1

624 ×0.8

PRM

548 ×0.8

IMMUN

Citations per year, relative to Jonathan R. Brody Jonathan R. Brody (= 1×) peers Tamer T. Önder

Countries citing papers authored by Jonathan R. Brody

Since Specialization

Citations

This map shows the geographic impact of Jonathan R. Brody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan R. Brody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan R. Brody more than expected).

Fields of papers citing papers by Jonathan R. Brody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan R. Brody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan R. Brody. The network helps show where Jonathan R. Brody may publish in the future.

Co-authorship network of co-authors of Jonathan R. Brody

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan R. Brody. A scholar is included among the top collaborators of Jonathan R. Brody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan R. Brody. Jonathan R. Brody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zarei, Mehrdad, Jonathan J. Hue, Ali Vaziri‐Gohar, et al.. (2024). IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Research. 84(18). 3072–3085. 10 indexed citations

Shupp, Alison B., et al.. (2021). Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2. Molecular Cancer Research. 19(10). 1763–1777. 8 indexed citations

Jain, Aditi, Chinnadurai Mani, Avinoam Nevler, et al.. (2021). AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Molecular Cancer Research. 19(4). 565–572. 16 indexed citations

Gmeiner, William H., David L. Caudell, Ralph B. D’Agostino, et al.. (2020). Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. Molecular Cancer Therapeutics. 20(3). 553–563. 14 indexed citations

Jain, Aditi, Alison B. Shupp, Avinoam Nevler, et al.. (2020). Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase–Dependent Manner. Molecular Cancer Research. 19(2). 207–214. 8 indexed citations

Pishvaian, Michael J., Hongkun Wang, Aiwu Ruth He, et al.. (2020). A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research. 26(19). 5092–5101. 32 indexed citations

Schultz, Christopher W., Aditi Jain, Austin Goetz, et al.. (2019). Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Molecular Cancer Research. 17(10). 2029–2041. 44 indexed citations

Pishvaian, Michael J., R Joseph Bender, Lola Rahib, et al.. (2018). Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research. 24(20). 5018–5027. 149 indexed citations

Nevler, Avinoam, Alexander J. Muller, Erika Sutanto‐Ward, et al.. (2018). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research. 25(2). 724–734. 41 indexed citations

10.

Hoang, David T., Lei Gu, Vitali Alexeev, et al.. (2018). STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clinical Cancer Research. 24(8). 1917–1931. 46 indexed citations

11.

Zarei, Mahsa, Shruti Lal, Seth J. Parker, et al.. (2017). Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Research. 77(16). 4460–4471. 84 indexed citations

12.

Lal, Shruti, Edwin Cheung, Mahsa Zarei, et al.. (2017). CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular Cancer Research. 15(6). 696–707. 41 indexed citations

13.

Chand, Saswati N., Mahsa Zarei, Matthew J. Schiewer, et al.. (2017). Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research. 77(18). 5011–5025. 64 indexed citations

14.

Huang, Yu-Hung, Weidan Peng, Jacquelyn Gerhart, et al.. (2016). Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Cancer Research. 76(6). 1549–1559. 75 indexed citations

15.

Zarei, Mahsa, Saswati N. Chand, Jordan M. Winter, et al.. (2016). HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Molecular Cancer Research. 14(7). 599–611. 48 indexed citations

16.

Lal, Shruti, Richard A. Burkhart, Neil Beeharry, et al.. (2014). HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Research. 74(4). 1128–1140. 83 indexed citations

17.

Burkhart, Richard A., Peng Yu, Renee Tholey, et al.. (2013). Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Molecular Cancer Research. 11(8). 901–911. 89 indexed citations

18.

Steffen, Jamin D., Renee Tholey, Marie-France Langelier, et al.. (2013). Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer. Cancer Research. 74(1). 31–37. 52 indexed citations

19.

Lin, Wan-Chi, Nirakar Rajbhandari, Chengbao Liu, et al.. (2013). Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer. Cancer Research. 73(6). 1821–1830. 60 indexed citations

20.

Costantino, Christina L., Agnieszka K. Witkiewicz, Yuki Kuwano, et al.. (2009). The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase. Cancer Research. 69(11). 4567–4572. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact